Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 10
1994 12
1995 26
1996 15
1997 13
1998 7
1999 9
2000 8
2001 11
2002 2
2003 3
2004 2
2005 1
2011 3
2012 3
2013 3
2014 12
2015 15
2016 21
2017 11
2018 2
2019 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
The oncogenic activation of beta-catenin.
Polakis P. Polakis P. Curr Opin Genet Dev. 1999 Feb;9(1):15-21. doi: 10.1016/s0959-437x(99)80003-3. Curr Opin Genet Dev. 1999. PMID: 10072352 Review.
Pharmaceutical biotechnology.
McCormick F, Wierenga W. McCormick F, et al. Curr Opin Biotechnol. 1995 Dec 1;6(6):621-3. doi: 10.1016/0958-1669(95)80102-2. Curr Opin Biotechnol. 1995. PMID: 8791304 No abstract available.
Ras signaling and NF1.
McCormick F. McCormick F. Curr Opin Genet Dev. 1995 Feb;5(1):51-5. doi: 10.1016/s0959-437x(95)90053-5. Curr Opin Genet Dev. 1995. PMID: 7749326 Review.
Interactions between Ras proteins and their effectors.
McCormick F, Wittinghofer A. McCormick F, et al. Curr Opin Biotechnol. 1996 Aug;7(4):449-56. doi: 10.1016/s0958-1669(96)80123-6. Curr Opin Biotechnol. 1996. PMID: 8768906 Review. No abstract available.
CDK inhibition and cancer therapy.
Garrett MD, Fattaey A. Garrett MD, et al. Curr Opin Genet Dev. 1999 Feb;9(1):104-11. doi: 10.1016/s0959-437x(99)80015-x. Curr Opin Genet Dev. 1999. PMID: 10072351 Review.
Signalling enzymes: bursting with potential.
Braselmann S, Palmer TM, Cook SJ. Braselmann S, et al. Curr Biol. 1997 Aug 1;7(8):R470-3. doi: 10.1016/s0960-9822(06)00239-9. Curr Biol. 1997. PMID: 9259544 Free article. Review.
Discovery of a novel Raf kinase inhibitor.
Lyons JF, Wilhelm S, Hibner B, Bollag G. Lyons JF, et al. Endocr Relat Cancer. 2001 Sep;8(3):219-25. doi: 10.1677/erc.0.0080219. Endocr Relat Cancer. 2001. PMID: 11566613 Free article. Review.
178 results